Pharmacokinetics and distribution of fluvoxamine to the brain in rats under oxidative stress

References

• Wilde MI, Plosker GL, Benfield P. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993;46:895–924.
   PubMed Web of Science ®Google Scholar
• Claghorn JL, Earl CQ, Walczak DD, Stoner KA, Wong LF, Kanter D, Houser VP. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol 1996;16:113–120.
   Google Scholar
• Mundo E, Rouillon F, Figuera ML, Stigler M. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol 2001;16:461–468.
   PubMed Web of Science ®Google Scholar
• Potter WZ, Rudorfer MV, Manji H. The pharmacologic treatment of depression. N Engl J Med 1991;325:633–642.
   PubMed Web of Science ®Google Scholar
• Rapaport M, Coccaro E, Sheline Y, Perse T, Holland P, Fabre L, Bradford D. A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 1996;16:373–378.
   PubMed Web of Science ®Google Scholar
• Wisner KL, Gelenberg AJ, Leonard H, Zarin D, Frank E. Pharmacologic treatment of depression during pregnancy. JAMA 1999;282:1264–1269.
   PubMed Web of Science ®Google Scholar
• Fluvoxamine (Luvox®) [Drug Information]. Astellas Pharma Inc. 2011.
   Google Scholar
• Bower S. Plasma protein binding of fentanyl: the effect of hyperlipoproteinaemia and chronic renal failure. J Pharm Pharmacol 1982;34:102–106.
   PubMed Web of Science ®Google Scholar
• Danon A, Chen Z. Binding of imipramine to plasma proteins: effect of hyperlipoproteinemia. Clin Pharmacol Ther 1979;25:316–321.
   PubMed Web of Science ®Google Scholar
• Oravcova J, Sojkova D, Fetkovska N, Trnovec T. Factors influencing isradipine and amlodipine binding to human plasma lipoproteins. Blood Press Suppl 1994;1:61–64.
   Google Scholar
• Fukushima K, Kobuchi S, Shibata M, Takada K, Sugioka N. Decrease in brain distribution of fluvoxamine in experimental hyperlipidemic rats. J Pharm Pharm Sci 2011;14:414–424.
   Google Scholar
• Alturfan AA, Emekli-Alturfan E, Uslu E. Consumption of pistachio nuts beneficially affected blood lipids and total antioxidant activity in rats fed a high-cholesterol diet. Folia Biol (Praha) 2009;55:132–136.
   Google Scholar
• Aruoma O. Free radicals, oxidative stress and antioxidants in health and disease. J Am Oil Chem Soc 1998;75:199–211.
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Cao B, Shibukawa A, Nakagawa T. Effect of oxidation of low-density lipoprotein on drug binding affinity studied by high performance frontal analysis-capillary electrophoresis. Electrophoresis 2001;22:3401–3407.
   PubMedGoogle Scholar
• Deiana M, Rosa A, Corona G, Collu S, Ennas MG, Dessi MA. Lipid peroxidation in plasma of rats treated with ferric- nitrilotriacetate, in relation to kidney and liver modifications. Biofactors 2005;23:35–44.
   PubMedGoogle Scholar
• Iqbal M, Giri U, Athar M. Ferric nitrilotriacetate (Fe-NTA) is a potent hepatic tumor promoter and acts through the generation of oxidative stress. Biochem Biophys Res Commun 1995;212:557–563.
   PubMed Web of Science ®Google Scholar
• Athar M, Iqbal M. Ferric nitrilotriacetate promotes N-diethylnitrosamine-induced renal tumorigenesis in the rat: implications for the involvement of oxidative stress. Carcinogenesis 1998;19:1133–1139.
   PubMed Web of Science ®Google Scholar
• Matsushita R, Kondo Y, Yada S, Miyamoto K. Proceedings of the 18th meeting of Japanese Society of Pharmaceutical Health Care and Sciences. Japanese Society of Pharmaceutical Health Care and Sciences; 2008 September 20 - 21; Sapporo. Japan: Japanese Society of Pharmaceutical Health Care and Sciences; 2008. 358 p.
   Google Scholar
• Kondo Y, Matsushita R, Yada S, Miyamoto K. Proceedings of the 25th Japanese Society of Therapeutic Drug Monitoring; 2008 June 21–22; Kobe. Japan: The Japanese Society of Therapeutic Drug Monitoring; 2008. 167 ps.
   Google Scholar
• Kobuchi S, Fukushima K, Aoyama H, Matsuda T, Ito Y, Sugioka N, Takada K. Effect of oxidative stress on the pharmacokinetics of clomipramine in rats treated with ferric- nitrilotriacetate. Drug Metabolism Letters 2011;5:243–252.
   PubMedGoogle Scholar
• Awai M, Narasaki M, Yamanoi Y, Seno S. Induction of diabetes in animals by parenteral administration of ferric nitrilotriacetate. A model of experimental hemochromatosis. Am J Pathol 1979;95:663–673.
   PubMed Web of Science ®Google Scholar
• Buege JA, Aust SD. Microsomal lipid peroxidation. Meth Enzymol 1978;52:302–310.
   PubMedGoogle Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–275.
   PubMed Web of Science ®Google Scholar
• Kurokawa S, Niwano S, Niwano H, Ishikawa S, Kishihara J, Aoyama Y, . Progression of ventricular remodeling and arrhythmia in the primary hyperoxidative state of glutathione-depleted rats. Circ J 2011;75(6):1386–93.
   Google Scholar
• Song Y, Xue Y, Liu X, Wang P, Liu L. Effects of acute exposure to aluminum on blood–brain barrier and the protection of zinc. Neurosci Lett 2008;445:42–46.
   PubMed Web of Science ®Google Scholar
• Schuhmacher J, Buhner K, Witt-Laido A. Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. J Pharm Sci 2000;89:1008–1021.
   PubMed Web of Science ®Google Scholar
• Terpstra AH, Woodward CJ, Sanchez-Muniz FJ. Improved techniques for the separation of serum lipoproteins by density gradient ultracentrifugation: visualization by prestaining and rapid separation of serum lipoproteins from small volumes of serum. Anal Biochem 1981;111:149–157.
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Fukushima K, Shibata M, Ito Y, Sugioka N, Takada K. Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats. J Pharm Pharmacol 2011;63:515–523.
   PubMed Web of Science ®Google Scholar
• Tournel G, Houdret N, Hedouin V, Deveau M, Gosset D, Lhermitte M. High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum. J Chromatogr B Biomed Sci Appl 2001;761:147–158.
   PubMed Web of Science ®Google Scholar
• Shinozuka T, Terada M, Tanaka E. Solid-phase extraction and analysis of 20 antidepressant drugs in human plasma by LC/MS with SSI method. Forensic Sci Int 2006;162:108–112.
   PubMed Web of Science ®Google Scholar
• Mates JM, Segura JA, Alonso FJ, Marquez J. Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. Arch Toxicol 2008;82: 273–299.
   PubMed Web of Science ®Google Scholar
• Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001; 281:G1135–G1139.
   PubMed Web of Science ®Google Scholar
• Matos HR, Capelozzi VL, Gomes OF, Mascio PD, Medeiros MH. Lycopene inhibits DNA damage and liver necrosis in rats treated with ferric nitrilotriacetate. Arch Biochem Biophys 2001;396:171–177.
   PubMed Web of Science ®Google Scholar
• Carini R, Parola M, Dianzani MU, Albano E. Mitochondrial damage and its role in causing hepatocyte injury during stimulation of lipid peroxidation by iron nitriloacetate. Arch Biochem Biophys 1992;297:110–118.
   PubMedGoogle Scholar
• Hamazaki S, Okada S, Li JL, Toyokuni S, Midorikawa O. Oxygen reduction and lipid peroxidation by iron chelates with special reference to ferric nitrilotriacetate. Arch Biochem Biophys 1989;272:10–17.
   PubMed Web of Science ®Google Scholar
• Ebina Y, Okada S, Hamazaki S, Ogino F, Li JL, Midorikawa O. Nephrotoxicity and renal cell carcinoma after use of iron- and aluminum-nitrilotriacetate complexes in rats. J Natl Cancer Inst 1986;76:107–113.
   PubMed Web of Science ®Google Scholar
• Ueno S, Kashimoto T, Susa N, Shiho K, Seki T, Ito N, . Estimation of hydroxyl radical generation by salicylate hydroxylation method in kidney of mice exposed to ferric nitrilotriacetate and potassium bromate. Free Radic Res 2007;41:1246–1252.
   PubMed Web of Science ®Google Scholar
• Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 1996;20:553–566.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Sun F, Tanaka K, Tokumaru S, Kojo S. Increase of lipid hydroperoxides in the rat liver and kidney after administering ferric nitrilotriacetate. Biosci Biotechnol Biochem 1998;62:1438–1439.
   PubMed Web of Science ®Google Scholar
• Rosa A, Deiana M, Corona G, Atzeri A, Incani A, Appendino G, Dessì MA. Protective effect of capsinoid on lipid peroxidation in rat tissues induced by Fe-NTA. Free Radic Res 2005;39(11):1155–62.
   Google Scholar
• Guo H, Ekusa A, Iwai K, Yonekura M, Takahata Y, Morimatsu F. Royal jelly peptides inhibit lipid peroxidation in vitro and in vivo. J Nutr Sci Vitaminol (Tokyo) 2008;54:191–195.
   PubMed Web of Science ®Google Scholar
• Prabu S, Shagirtha K, Renugadevi J. Amelioration of cadmium-induced oxidative stress, impairment in lipids and plasma lipoproteins by the combined treatment with quercetin and α-tocopherol in rats. J Food Sci 2010;75:132–140.
   PubMed Web of Science ®Google Scholar
• Newairy AS, Abdou HM. Protective role of flax lignans against lead acetate induced oxidative damage and hyperlipidemia in rats. Food Chem Toxicol 2009;47:813–818.
   PubMed Web of Science ®Google Scholar
• Whitlam JB, Brown KF. Ultrafiltration in serum protein binding determinations. J Pharm Sci 1981;70:146–150.
   Google Scholar
• Barre J, Chamouard JM, Houin G, Tillement JP. Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma–protein-binding characteristics of valproic acid. Clin Chem 1985;31:60–64.
   PubMed Web of Science ®Google Scholar
• Simon N, Dailly E, Combes O, Malaurie E, Lemaire M, Tillement JP, Urien S. Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin. Br J Clin Pharmacol 1998;45:173–175.
   Google Scholar
• Luvox® CR (Fluvoxamine maleate) [Drug Information]. Jazz Pharmaceuticals, Inc. 2009.
   Google Scholar
• Lapenna D, Ciofani G, Pierdomenico SD, Neri M, Giamberardino MA, Cuccurullo F. Amiodarone inhibits tocopherol-mediated human lipoprotein peroxidation. Biochem Pharmacol 2007;74:265–272.
   PubMed Web of Science ®Google Scholar
• Urien S, Riant P, Albengres E, Brioude R, Tillement JP. In vitro studies on the distribution of probucol among human plasma lipoproteins. Mol Pharmacol 1984;26:322–327.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ohkubo N, Aoto M, Maeda N, Cicha I, Miki T, Mitsuda N. Participation of caspase-3-like protease in oxidation-induced impairment of erythrocyte membrane properties. Biorheology 2007;44:179–190.
   PubMedGoogle Scholar
• Sato N, Takada H, Tsukui M, Takebayashi T, Fuji K, Hiranuma T, Aizawa K, Nakayoshi T. Studies on the pharmacokinetics of fluvoxamine maleate (3): Plasma concentration profile and brain distribution in rats. Jpn Pharmacol Ther 1995;23(3):85–91.
   Google Scholar
• Spigset O, Axelsson S, Norstrom A, Hagg S, Dahlqvist R. The major fluvoxamine metabolite in urine is formed by CYP2D6. Eur J Clin Pharmacol 2001;57:653–658.
   PubMed Web of Science ®Google Scholar
• Hogberg J, Bergstrand A, Jakobsson SV. Lipid peroxidation of rat-liver microsomes. Its effect on the microsomal membrane and some membrane-bound microsomal enzymes. Eur J Biochem 1973;37:51–59.
   PubMedGoogle Scholar
• Cederbaum AI. Iron and CYP2E1-dependent oxidative stress and toxicity. Alcohol 2003;30:115–120.
   PubMedGoogle Scholar
• Smedsrod B, Melkko J, Araki N, Sano H, Horiuchi S. Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem J 1997;322:567–573.
   PubMed Web of Science ®Google Scholar
• Nagelkerke JF, Barto KP, van Berkel TJ. In vivo and in vitro uptake and degradation of acetylated low density lipoprotein by rat liver endothelial, Kupffer, and parenchymal cells. J Biol Chem 1983;258:12221–12227.
   PubMed Web of Science ®Google Scholar
• Geldof M, Freijer J, van Beijsterveldt L, Danhof M. Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat. Pharm Res 2008;25:792–804.
   Google Scholar
• Geldof M, Freijer J, van Beijsterveldt L, Timmerman P, Ahnaou A, Drinkenburg WH, Danhof M. Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies. Eur J Pharm Sci 2007;30:45–55.
   Google Scholar
• De Vries MH, Van Harten J, Van Bemmel P, Raghoebar M. Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects. Biopharm Drug Dispos 1993;14:291–296.
   Google Scholar
• Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994;27:175–190.
   PubMed Web of Science ®Google Scholar
• Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, . The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos Biol Fate Chem 2005;33: 165–174.
   PubMed Web of Science ®Google Scholar
• Wu J, Ji H, Wang YY, Wang Y, Li YQ, Li WG, Long Y, . Glutathione depletion upregulates P-glycoprotein expression at the blood–brain barrier in rats. J Pharm Pharmacol 2009;61: 819–824.
   Google Scholar
• Hong H, Lu Y, Ji ZN, Liu GQ. Up-regulation of P-glycoprotein expression by glutathione depletion-induced oxidative stress in rat brain microvessel endothelial cells. J Neurochem 2006;98:1465–1473.
   PubMed Web of Science ®Google Scholar